Loading company…
Rezolute develops therapies for rare diseases, including congenital and tumor hyperinsulinism.
Founded in 2010 and based in Redwood City, US, Rezolute develops treatments for rare diseases, including congenital and tumor hyperinsulinism. In May 2022, it raised USD 44.20 mn in a private placement or follow-on round to support clinical development of RZ358 and RZ402.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in